Recent News

• 03.30.2026 - INmune Bio Inc. Announces 2025 Results and Provides Business Update
• 03.19.2026 - INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
• 02.23.2026 - INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
• 02.19.2026 - INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
• 02.12.2026 - INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease
• 02.10.2026 - INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
• 01.27.2026 - INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives

Recent Filings

• 02.27.2026 - 8-K Current report
• 02.27.2026 - EX-99.1 EX-99.1
• 02.23.2026 - 8-K Current report
• 02.23.2026 - EX-99.1 EX-99.1
• 02.19.2026 - EX-99.1 EX-99.1
• 02.19.2026 - 8-K Current report
• 02.13.2026 - 8-K Current report
• 02.13.2026 - EX-99.1 EX-99.1
• 01.27.2026 - 8-K Current report
• 01.27.2026 - EX-99.1 EX-99.1